Charles River Laboratories International, Inc. (CRL)
NYSE · Health Care · market cap 8.70B
Share price
$338.46
At the last nightly close
Intrinsic value
$103.35
Range $103.35 – $210.05 — the conservative figure is the low end.
Margin of safety
-69.5%
($103.35 − $338.46) ÷ $338.46
EV / EBIT
57.7
On the median operating profit of 15 fiscal years through 2025.
How these numbers are computed
The valuations are calculated in Python from filed accounts, not written by a language model. Three methods run side by side: earnings power value, which capitalises a normalised operating profit; a free-cash-flow model; and the Graham Number as an asset-side cross-check. The conservative figure above starts from the lower of the first two; the Graham Number never enters it.
The frame gives no credit for growth unless the company has earned it: only a return on invested capital that has beaten the cost of capital year after year earns a growth credit, and that credit is capped. A company that compounds will therefore usually read as expensive against it — that is deliberate. It is a price-discipline floor, not a price target, and it is not a view on what the shares will do.
The EV/EBIT ranking uses the median operating profit of up to fifteen fiscal years — a full cycle — where the free screeners use the last twelve months. When the data cannot support a method, the figure reads n/a rather than a number: a free-cash-flow valuation on a bank, a PEG on erratic earnings, a multiple on a company with no operating profit to speak of.
Fundamentals from SEC EDGAR. Prices, market data and technicals from yfinance. Valuation computed 2026-10-22.
Key metrics
Market position
Annual financials
| Period | Revenue | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|
| 2025-FY | 4.02B | 401.1M | -144.3M | -2.91 | 518.5M |
| 2024-FY | 4.05B | 442.3M | 10.3M | 0.20 | 501.6M |
| 2023-FY | 4.13B | 617.3M | 474.6M | 9.27 | 365.4M |
| 2022-FY | 3.98B | 651.0M | 486.2M | 9.57 | 294.9M |
| 2021-FY | 3.54B | 589.9M | 391.0M | 7.60 | 532.0M |
Filed figures from SEC EDGAR, in the reporting currency.
Next earnings
Recent news
- Why Charles River Laboratories (CRL) Stock Is Up Today | Quiver Quantitativequiverquant.com
- Charles River Sets Nov. 4 Q3 2026 Earnings Call | CRL Stock Newsstocktitan.net
- CRL Stock | Charles River Laboratories Intl. Q1 2026 Earnings Callyoutube.com
- Charles River: CRL Stock Price Quote & News | Robinhoodrobinhood.com
- Charles River Laboratories International, Inc. (CRL) Stock Price, News, Quote & History - Yahoo Financefinance.yahoo.com
Headlines link to their source. Sperio does not republish article text.
The figures above are the arithmetic. To see what a board of eight AI agents makes of them — macro, sector, filings, news and a devil's advocate whose only job is to attack the thesis — run the full analysis on CRL.
Run the board on CRL10 free analyses · no signup, no card
This page presents computed figures and filed financial data for information only. It is not investment advice, not a recommendation to buy or sell any security, and not a statement about what these shares will do. Sperio is a research tool, not an investment adviser. Figures are derived automatically from public filings and market data and may be incomplete, out of date or wrong. See the Terms & Disclaimer.